UniProtKB/Swiss-Prot Q04837: Variant p.Arg107Gln

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 107 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Arginine (R) to Glutamine (Q) at position 107 (R107Q, p.Arg107Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In OPA13; reduced ability to stimulate POLG-dependent DNA synthesis in vitro. Any additional useful information about the variant.

Sequence information

Variant position: 107 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 148 The length of the canonical sequence.
Location on the sequence: ISVFRPGLRDVAYQYVKKGS R IYLEGKIDYGEYMDKNNVRR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	17 – 148	Single-stranded DNA-binding protein, mitochondrial
Domain	30 – 141	SSB
Modified residue	113 – 113	N6-acetyllysine
Modified residue	122 – 122	N6-succinyllysine
Beta strand	107 – 115

Literature citations

SSBP1 mutations in dominant optic atrophy with variable retinal degeneration.
Jurkute N.; Leu C.; Pogoda H.M.; Arno G.; Robson A.G.; Nuernberg G.; Altmueller J.; Thiele H.; Motameny S.; Toliat M.R.; Powell K.; Hoehne W.; Michaelides M.; Webster A.R.; Moore A.T.; Hammerschmidt M.; Nuernberg P.; Yu-Wai-Man P.; Votruba M.;
Ann. Neurol. 86:368-383(2019)
Cited for: INVOLVEMENT IN OPA13; VARIANTS OPA13 GLN-38; GLN-107 AND ASN-141; SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder.
Del Dotto V.; Ullah F.; Di Meo I.; Magini P.; Gusic M.; Maresca A.; Caporali L.; Palombo F.; Tagliavini F.; Baugh E.H.; Macao B.; Szilagyi Z.; Peron C.; Gustafson M.A.; Khan K.; La Morgia C.; Barboni P.; Carbonelli M.; Valentino M.L.; Liguori R.; Shashi V.; Sullivan J.; Nagaraj S.; El-Dairi M.; Iannaccone A.; Cutcutache I.; Bertini E.; Carrozzo R.; Emma F.; Diomedi-Camassei F.; Zanna C.; Armstrong M.; Page M.; Stong N.; Boesch S.; Kopajtich R.; Wortmann S.; Sperl W.; Davis E.E.; Copeland W.C.; Seri M.; Falkenberg M.; Prokisch H.; Katsanis N.; Tiranti V.; Pippucci T.; Carelli V.;
J. Clin. Invest. 130:108-125(2020)
Cited for: VARIANTS OPA13 VAL-40; ASP-62; GLN-107 AND GLN-111; VARIANT VAL-132; CHARACTERIZATION OF VARIANTS OPA13 VAL-40; ASP-62; GLN-107 AND GLN-111; CHARACTERIZATION OF VARIANT VAL-132; FUNCTION; SUBCELLULAR LOCATION; SUBUNIT; Dominant mutations in mtDNA maintenance gene SSBP1 cause optic atrophy and foveopathy.
Piro-Megy C.; Sarzi E.; Tarres-Sole A.; Pequignot M.; Hensen F.; Quiles M.; Manes G.; Chakraborty A.; Senechal A.; Bocquet B.; Cazevieille C.; Roubertie A.; Mueller A.; Charif M.; Goudenege D.; Lenaers G.; Wilhelm H.; Kellner U.; Weisschuh N.; Wissinger B.; Zanlonghi X.; Hamel C.; Spelbrink J.N.; Sola M.; Delettre C.;
J. Clin. Invest. 130:143-156(2020)
Cited for: VARIANTS OPA13 GLN-38 AND GLN-107; CHARACTERIZATION OF VARIANT OPA13 GLN-38; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 16-148;